
Dr Solange Corriol-Rohou, Senior Director, Global Regulatory Affairs & Policy, Europe, at AstraZeneca Global Medicines Development, discusses DIA’s upcoming Value, …

Janssen has revealed that its CD38-targeting biologic drug Darzalex (daratumumab) has received approval from the European Commission, authorising its use …
The US multinational Pfizer has said that Brexit will cost the company $100 million in costs associated with the transference …

Cancer treatment is making leaps and bounds, but public focus tends to gravitate towards the therapies themselves. Matt Fellows explores …

A group of Dutch doctors and health advocates are taking action against the Italian pharmaceutical firm Leadiant Biosciences who have …

The new September edition of Pharmafocus is now live and available to read online. We’re entering the final stretch as …

Eight months of 2018 down – where has the year gone? As we move from August into September, and a …

Shire has completed the sale of its oncology franchise to French firm Servier for $2.4 billion, handing over the global …

AstraZeneca and its biologics R&D arm MedImmune have released a statement admitting that their fully human monoclonal antibody anifrolumab failed …

AstraZeneca has announced that its auto-injector Bydureon BCise (exenatide 2mg prolonged-release suspension) has been approved by the European Commission for …

Jazz Pharmaceuticals has revealed that its advanced liposomal formulation Vyxeos has received approval from the European Commission for the treatment …

Emergent BioSolutions has announced it has signed an agreement to acquire Adapt Pharma at a valuation of $735 million, a …

The FDA has opted to refuse approval to Akcea and Ionis’ Waylivra (volanesorsen) for the treatment of the ultra-rare hereditary …

Almost one full year since the treatment was given a “historic” approval in the US, Novartis’ CAR T therapy Kymriah …

Milan-based biotech firm Dompé has revealed that the FDA has awarded approval in the US to its Oxervate (cenegermin-bkbj ophthalmic …